Imagenebio, Inc. · NASDAQ:IMA
Imagenebio — Investor Presentation (July 2025)
36 slides from Imagenebio's investor presentation, Jul 29, 2025
Slide 1: Corporate Overview July 2025
Exhibit 99.1 Corporate Overview July 2025
Slide 2: Disclaimer
Disclaimer This presentation contains “forward-looking statements” under the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ImageneBio, Inc.’s (“Imagene’s”) actual results may differ from their expectations, estimates and projections and consequently
Slide 3: Imagene overview
Imagene overview § Clinical stage biopharmaceutical company developing potentially differentiated therapies for the treatment of immunology and inflammatory (I & I) disorders § Lead program, IMG-007, is an ADCC-silenced, half-life extended, non-depleting anti-OX40 mAb o Results from Phase 2a AD tria
Slide 4: Imagene leadership team
Imagene leadership team Kristin Yarema, PhD Yufang Lu, MD, PhD Jotin Marango, MD, PhD Chief Executive Officer Chief Financial Officer Chief Medical Officer 20+ years of leadership in executive 20+ years of experience in drug 20+ years of experience in management, clinical development, development an
Slide 5: Market potential for IMG-007 estimated at ~$5bn
1 Market potential for IMG-007 estimated at ~ $5bn Indication(s) Eligible Population Current Status Atopic dermatitis ~3.0M Phase 2b (AD) Alopecia Areata ~0.6M Expansion Opportunity (AA) Asthma ~1.9M Expansion Opportunity IMG-007 2 Other Indications TBD Expansion Opportunity Total Opportunity ~5.5M
Slide 6: IMG-007 in Atopic Dermatitis (AD)
IMG-007 in Atopic Dermatitis (AD) 6
Slide 7: Addressing unmet need in treatment of atopic dermatitis
Addressing unmet need in treatment of atopic dermatitis AD presents a diverse clinical course and AD is a chronic relapsing disease that requires long- presentation due to heterogenous molecular endotypes term management Currently approved biologics target Th2 pathway (IL13, Currently approved biolo
Slide 8: IMG-007: OX40 mAb with silenced ADCC and long half-life
IMG-007: OX40 mAb with silenced ADCC and long half-life IMG-007 antibody design § IgG1 mAb targeting OX40 Fab Fab 1 § ADCC silenced to minimize safety risk 2 § Extended half-life supports the potential of 3 Q24W for maintenance therapy N297A Mutations Fc ADCC is a cytotoxic effector mechanism by whi
Slide 9: Advantages of binding OX40 receptor versus OX40 ligand
Advantages of binding OX40 receptor versus OX40 ligand 1 Illustrative OX40/OX40L interaction Anti-OX40 Anti-OX40L Block OX40/L signaling in: ü Blood ü ü Tissues § An anti-OX40 mAb can engage its target in both blood and tissues vs. an anti-OX40L mAb predominantly in tissues § Targeting OX40L is limi
Slide 10: IMG-007's potential advantages compared to anti-Th2 mAbs
IMG-007’s potential advantages compared to anti-Th2 mAbs Target Anti-OX40 mAb Anti-Th2 (IL-4, IL- IMG-007 has the potential: pathway IMG-007 13, IL-31) mAbs § to address more diverse clinical phenotypes Th1 ü by targeting a broader range of T cell subtypes than Th2 targeting biologics Th2 üü § to pr
Slide 11: Ph2a trial in adult patients with moderate-to-severe AD
IMG-007 Ph2a trial in adult patients with moderate-to-severe AD 1 1 Trial design Baseline characteristics Mean Age, years (SD): 49.8 (15.0) Sex: Female 30.8%, Male 69.2% Mean BMI (SD): 31.4 (8.7) Race: Caucasian: 46.2%, Non-Caucasian: 53.8% Mean duration of AD, years 29.6 (19.8) (SD): § Monotherapy
Slide 12: IMG-007 was generally well-tolerated in Ph2a atopic dermatitis trial
IMG-007 was generally well-tolerated in Ph2a atopic dermatitis trial 1 Overall summary of treatment-emergent adverse events § There were no serious adverse events, Participants with at least one TEAE 9 (69.2%) no treatment-related AEs, no infusion- related reactions, no reports of pyrexia Study trea
Slide 13: Pyrexia and chills are commonly observed in rocatinlimab's clinical trials
* Pyrexia and chills are commonly observed in rocatinlimab’s clinical trials 1 2 Rocatinlimab tolerability in Ph2b AD study Rocatinlimab tolerability in Ph1 HV study 50% Pyrexia 36.4% Chills (N=22) (N=22) Pyrexia Chills Dose-related increase in the incidences of pyrexia and chills in rocatinlimab Ph
Slide 14: Ph2a AD study: PK sustained well above EC90 for weeks
IMG-007 Ph2a AD study: PK sustained well above EC90 for 24 weeks 1 Drug concentration in the blood § With 3x 300 mg IV doses over 4 weeks, the mean serum drug concentration was maintained well above the EC90, concentration needed for OX40 target engagement in the blood, for 24 weeks § The robust PK
Slide 15: AD Ph2a: rapid onset of clinical activity; sustained for months
IMG-007 AD Ph2a: rapid onset of clinical activity; sustained for 6 months Percent (%) change from Percent (%) change from Percent (%) change from baseline in EASI score baseline in O-SCORAD score baseline in BSA score 0 1 2 4 6 8 12 16 20 24 0 1 2 4 6 8 12 16 20 24 0 1 2 4 6 8 12 16 20 24 Analysis t
Slide 16: IMG-007's Ph2a data and rocatinlimab's historical POC data
1 IMG-007’s Ph2a data and rocatinlimab’s historical POC data Percent (%) change from baseline in EASI score Percent (%) change from baseline in EASI score (Rocatinlimab’s historical POC data) (IMG-007 Ph2a data) 1.Rocatinlimab’s historical AD proof-of-concept (POC) trial: Nakagawa H et al. J Dermato
Slide 17: AD Ph2a: durable activity based on EASI responder endpoints
IMG-007 AD Ph2a: durable activity based on EASI responder endpoints Proportion of patients achieving EASI-75 and EASI-90 W0 W1 W2 W4 W6 W8 W12 W16 W20 W24 3 IV doses 300 mg Q2W N=13; Patients who received rescue therapies were counted as “non-responders”. Last observation carried forward (LOCF) impu
Slide 18: Clinical activity of rocatinlimab and amlitelimab in Ph2b AD studies
* Clinical activity of rocatinlimab and amlitelimab in Ph2b AD studies Key clinical activity data of amlitelimab Key clinical activity data of rocatinlimab 2 1 in Ph2b AD study in Ph2b AD study Rocatinlimab Amlitelimab Phase 2b Phase 2b (N=52) (N=77) Treatment period 18 weeks Treatment period 24 wee
Slide 19: AD Ph2a: Th1/2/17 biomarkers depressed after 4-week treatment
IMG-007 AD Ph2a: Th1/2/17 biomarkers depressed after 4-week treatment Th1 Serum Proteins (Mean ± SEM) Th2 Serum Proteins (Mean ± SEM) Th17 Serum Proteins (Mean ± SEM) * p<0.05 ** p<0.01; Two-way ANOVA with Dunnett’s multiple comparisons test; SEM: standard error of the mean N numbers at baseline, wk
Slide 20: AD Ph2a: inhibition of Th1/2/17 serum markers
IMG-007 AD Ph2a: inhibition of Th1/2/17 serum markers 0 . 2 Th1 Th2 Th17 0 . 1 WK 1 4 16 24 1 4 16 24 WK 1 4 16 24 1 4 16 24 WK 1 4 16 24 1 4 16 24 0 . 0 0.0 0.0 - 0 . 1 -0.1 -0.2 - 0 . 2 -0.2 -0.4 - 0 . 3 -0.3 - 0 . 4 -0.6 -0.4 CCL17 CCL7 CXCL8 IL1B IL17F MMP12 FC: fold change, Log10 (FC vs Baselin
Slide 21: IMG-007 subcutaneous formulation has been developed
IMG-007 subcutaneous formulation has been developed § Imagene has developed a subcutaneous formulation, which will be used in Ph2b and later studies § A SC/IV PK bridging study in healthy adults has been completed § The SC formulation is at a concentration of 150 mg/mL § GMP manufacturing process ha
Slide 22: SC PK study: robust PK profile
IMG-007 SC PK study: robust PK profile 1 Concentration-time profile (single dose) § IMG-007’s SC formulation showed a robust PK (Mean ±SD; semi-log scale) profile, similar to the IV formulation § A single 600 mg SC dose showed a long half- 3 life, estimated to be ~34.7 days § IMG-007 was well-tolera
Slide 23: Half-life data for rocatinlimab and amlitelimab
* Half-life data for rocatinlimab and amlitelimab Half-life data for amlitelimab Half-life data for rocatinlimab (an anti-OX40L mAb) (an anti-OX40 mAb with enhanced ADCC function) § A single IV dose of 4 mg/kg amlitelimab on Day 1 § A single SC dose of 3 mg/kg rocatinlimab followed with 2 mg/kg on D
Slide 24: AD Ph2b study design
IMG-007 AD Ph2b study design Screening Period 1: Placebo-controlled Period 2: Active Treatment Follow-up Period Period Treatment IMG-007 high dose IMG-007 high dose IMG-007 medium dose IMG-007 medium dose IMG-007 low dose IMG-007 low dose IMG-007 high dose Placebo W-5 W0 W20 W52 W68 Screening Baseli
Slide 25: IMG-007 clinical development plan for atopic dermatitis
IMG-007 clinical development plan for atopic dermatitis 2026 20232023 2024 2024 2025 2025+ 2022 2027 & + Phase 1 (IV) in Ph2a (IV) in AD Healthy Adults Interim EOS Phase 1 (SC) in 1 Ph2b (SC) Dose Ranging in AD Healthy Adults Primary PK/Safety Ph3 (SC) in AD 1 First patient dosed in the Phase 2b AD
Slide 26: IMG-007 in Alopecia Areata (AA)
IMG-007 in Alopecia Areata (AA) 26
Slide 27: Global AA Market Size
Global AA Market Size +110% $8 B $6.92 B $7 B $6.43 B Market is projected to increase at a $5.97 B CAGR of ~7.6% from 2024 to 2034, $6 B $5.55 B resulting in a total ~110% increase $5.16 B $4.80 B $5 B $4.46 B $4.14 B $3.85 B $4 B $3.58 B $3.32 B $3.09 B $3 B $2 B $1 B $0 B 2023 2024 2025 2026 2027
Slide 28: AA is a large market with high unmet need for safe & effective drugs
AA is a large market with high unmet need for safe & effective drugs § The lifetime incidence risk of AA in the general 1 population was estimated to be ~2% Boxed warnings for FDA-approved JAK 4 inhibitors for AA § AA has a profound negative impact on the patient’s quality of life and wellbeing§ Ser
Slide 29: Global Phase 2a AA study design
IMG-007: Global Phase 2a AA study design IMG-007-202: a proof-of-concept study to evaluate the safe, PK and efficacy of IMG-007 in AA patients with ≥ 50% scalp hair loss Treatment Follow-up Screening (4 weeks) (up to Week 36) Cohort 1 300 mg, Q2W, 3 IV over 4 weeks (N~6) (safety run-in) W24 W36 D1 W
Slide 30: Ph2a AA study: key baseline AA characteristics
IMG-007 Ph2a AA study: key baseline AA characteristics § 29 patients were enrolled from 11 centers in the U.S. and Canada (N=6 in Cohort 1 and N=23 in Cohort 2) § Mean duration of current AA episode of 3.0 years § Mean SALT score of 80.4 § 69% of all patients had SALT scores 50 to <95, and 31% had s
Slide 31: IMG-007 was overall well-tolerated in Ph2a AA study
IMG-007 was overall well-tolerated in Ph2a AA study IMG-007 300 mg IMG-007 600 mg All IMG-007 (N=6) (N=23) (N=29) Main study up to 24 weeks § IMG-007 was generally well tolerated Participants with at least one TEAE 3 (50.0) 19 (82.6) 22 (75.9) § There were no SAEs Study treatment related TEAE 2 (33.
Slide 32: 4-week treatment resulted in a dose-related improvement in SALT score
4-week treatment resulted in a dose-related improvement in SALT score Patients in the 600 mg cohort showed greater improvement in SALT score than in the 300 mg cohort (Baseline SALT 50 - 100) Mean % change from baseline in SALT score % Patients achieving ≥ 30% improvement in SALT score (SALT30) Wk 1
Slide 33: Marked improvement seen in patients with baseline SALT score 50 to <95
Marked improvement seen in patients with baseline SALT score 50 to < 95 Four-week (600 mg) treatment led to deeper improvement in patients with baseline SALT score 50 - < 95 than in patients with baseline SALT 95 - 100 % Patients achieving ≥ 30% improvement in Mean % change from baseline in SALT sco
Slide 34: Durable suppression of inflammatory markers in the AA lesional scalp
Durable suppression of inflammatory markers in the AA lesional scalp 2 Fold change in lesional vs. non-lesional scalp skin (Mean ± SEM) (three IV doses of 600 mg at Week 0, 2 and 4) Th2 CD8+ T Th1 NS ** ** 2.5 2.5 2.5 2.0 2.0 2.0 1.5 1.5 1.5 Activations of diverse (Th1 & Th2, and Levels in CD8+) T c
Slide 35: Photos showing improvement in IMG-007 Ph2a AA trial
Photos showing improvement in IMG-007 Ph2a AA trial After 3 IV 600 mg doses at Week 0, 2 and 4 Week 16 Baseline Week 24 Week 36 35
Slide 36: Ss IMAG
N Wy N q 4 ¥ 4 Ss IMAG \N i)